Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2022 Annual Meeting | C62 - Alzheimer's Disease

Monday 04/04/22
07:00 AM - 09:00 AM PDT Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Liana Apostolova, MD, FAAN
Aging, Dementia, Cognitive, and Behavioral Neurology
During this course participants will be introduced to the concept of AD as a clinicopathologic entity and explain approaches to detect AD early in the disease continuum; discuss the range of biomarker breakthroughs to detect AD and the role of these tools in research and in clinical practice; discuss the importance of integrating clinical assessment and biomarkers to obtain an early diagnosis; recognize and understand the clinical heterogeneity in AD; discuss the most recent therapeutic advances and emerging therapies for Alzheimer's disease; discuss the Appropriate Use Recommendations for Aducanumab
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement
Intermediate
Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student
Didactic

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:50 AM PDT Speaker Approaches to Detect Alzheimer's Disease Early in the Disease Continuum
Liana Apostolova, MD, FAAN
07:00 AM - 07:00 AM PDT Speaker walk in slides
Liana Apostolova, MD, FAAN
07:50 AM - 08:00 AM PDT Q&A Questions and Answers
Liana Apostolova, MD, FAAN
08:00 AM - 08:45 AM PDT Speaker Anti-Amyloid Antibody Therapies in Alzheimer’s Disease: Appropriate Use Criteria for Aducanumab
Liana Apostolova, MD, FAAN
08:45 AM - 09:00 AM PDT Q&A Questions and Answers
Liana Apostolova, MD, FAAN
Faculty Disclosures
Liana Apostolova, MD, FAAN Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NIH. Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Apostolova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Apostolova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Apostolova has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Apostolova has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Apostolova has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Alzheimer Association. An immediate family member of Dr. Apostolova has stock in Cassava Neurosciences. The institution of Dr. Apostolova has received research support from Roche Diagnostics. The institution of Dr. Apostolova has received research support from NIA. The institution of Dr. Apostolova has received research support from Alzheimer Association. The institution of Dr. Apostolova has received research support from AVID radiopharmaceuticals. The institution of Dr. Apostolova has received research support from Life Molecular Imaging.